(The Epoch Times)—Toddlers and other young children faced a higher risk of seizures shortly after COVID-19 vaccination, according to a new study from U.S. Food and Drug Administration (FDA) researchers.
The incidence of febrile seizures was 2.5 times higher among children zero to one day after a Moderna shot, compared to the same children eight to 63 days after vaccination, the researchers said.
That risk was “significantly elevated,” they wrote in a preprint paper describing the results.
There was also a higher risk for febrile seizures zero to one day after receipt of a Pfizer-BioNTech dose, compared to the same 8–63 day window following vaccination, but that elevated risk was not statistically significant.
Richard Forshee, deputy director of the FDA’s Office of Biostatistics and Pharmacovigilance, and other researchers conducted the self-controlled case series by analyzing data from commercial databases. The data came from CVS Health, Optum, and Carelon Research. The children were 2 to 5 years old.
Fever is a common side effect of the COVID-19 vaccines. Some 19 percent of children aged 2 to 3, for instance, in Pfizer’s clinical trial suffered fever after a second dose. Fever may result in some cases in febrile seizures, health officials said.
The study was carried out after the researchers identified seizures/convulsions as a safety signal among children aged 2 to 4 following receipt of Pfizer’s shot and among children aged 2 to 5 after a Moderna jab. Further research was needed because the method of identification, near real-time surveillance, “was designed to be sensitive but not specific for screening and detection purposes,” the researchers said. Febrile seizures became the focus because most of the cases identified in the prior study were seizures of that type.
The two-day window utilized in the new study ensures the seizure cases “are more likely to be associated with vaccination rather than other causes,” the researchers said.
There were 88 febrile seizures after the Pfizer vaccination among the study population. Seven of those cases happened the day of, or the day after, vaccination.
There were 67 cases after the Moderna vaccination. Ten happened in the two-day window.
Seizures that happened two to seven days after vaccination were excluded from the primary analysis.
In a secondary analysis, using a longer risk interval within seven days of vaccination, researchers identified 103 febrile seizures and 135 seizures/convulsions after Pfizer vaccination, including 22 febrile seizures and 32 seizures/convulsions within seven days of a shot. The secondary analysis showed 78 febrile seizures and 106 seizures/convulsions after Moderna vaccination, including 21 febrile seizures and 28 seizures/convulsions in the longer risk interval.
No statistically significant findings showed up for that secondary analysis, or any other secondary analyses, after researchers applied adjustments to the data.
Exclusions included children who received more doses than approved. Researchers analyzed data from the Carelon database from June 2022 to February 2023, from June 2022 to March 2023 from the CVS database, and from June 2022 to May 2023 in the Optum database.
The FDA authorized new versions of vaccines from Pfizer, Moderna, and Novavax in late 2023, relying on clinical trial data from just 50 humans. Those currently available versions are not covered by the research.
The FDA funded the new study. Limitations of the research included the small number of cases, according to the researchers.
Dr. Harvey Risch, professor emeritus of epidemiology at the Yale School of Public Health, who was not involved in the research, agreed. “These small numbers are not large enough for a reliable statistical analysis, which makes the paper scientifically weak,” Dr. Risch told The Epoch Times in an email.
The corresponding author, Mr. Forshee, did not respond to a request for comment. The FDA declined to comment. Moderna and Pfizer did not return inquiries.
Despite the finding of elevated risk, the researchers claimed that “based on the current body of scientific evidence, the safety profile of the monovalent mRNA vaccines remains favorable for use in young children.”
At Last, a Company With Integrity in the Gold IRA Industry
For several years, I’ve been vetting out precious metals companies in search of the best. I believe in gold and silver but it’s hard to find integrity in the Gold IRA industry. The vast majority operate with shady tactics and gigantic spreads that take advantage of Americans who simply want to protect their life’s savings.
I’ve found a handful that I like and I’ve worked with some of them. By no means would I “unrecommend” them because, again, I vetted them out and found them to be above the fold. Unfortunately, it isn’t hard to be better than the rest when the rest are so darn awful.
After years of searching, I finally found a company that truly operates with integrity. Augusta Precious Metals has three important attributes that set them far above the competition:
- Non-Commissioned Sales Team: I cannot stress how important and unique this is. With just about every other company in the Gold IRA industry, the sales teams make commission from every account they open. This means they steer their clients toward the gold and silver products with the highest commission. With Augusta Precious Metals, the team is solely focused on putting the best gold and silver for their clients into their IRA. They get paid to serve the best interests of the Gold IRA client, NOT their own commission pay.
- Incredibly Low Fees: Most Americans would be shocked if they knew the spread other Gold IRA companies charge. Augusta charges just 5% versus up to 45% elsewhere.
- No Pressure, No Gimmicks: There’s an understanding among most in the Gold IRA industry that fear and pressure is the way to go. Augusta Precious Metals takes a sober approach when working with clients because they hold integrity in the highest possible regard. This is why they don’t offer gimmicks like “free” or “bonus” silver. It’s also why they do not apply pressure tactics to get quick sales. Their educational and transparent approach to doing business is exceedingly rare in the Gold IRA industry.
